Australia, 24th Mar 2025, – Neuralia TMS, a leader in non-invasive therapeutic treatments, has announced the expansion of its services to include pharmacogenetic testing across Australia. This new offering enables the company to enhance its ability to tailor treatments to the specific needs of individual patients. The integration of pharmacogenetic testing into Neuralia TMS’s service portfolio further advances the company’s personalised approach to mental health and chronic pain management.
Pharmacogenetic testing involves analysing an individual’s genetic profile to assess how they may respond to specific medications. By combining this testing with existing therapies such as Transcranial Magnetic Stimulation (TMS) and Transcranial Direct Current Stimulation (tDCS), Neuralia TMS can offer more customised treatment plans for conditions such as depression, anxiety, PTSD, OCD, chronic pain, and Parkinson’s disease.
“By incorporating pharmacogenetic testing, Neuralia TMS can now offer therapies that are more precisely aligned with each individual’s genetic profile. This step allows for a more personalised and targeted approach to treatment,” said a spokesperson for Neuralia TMS. “It enables patients to receive care that is more effective while minimising potential side effects associated with less tailored treatments.”
Neuralia TMS is known for its non-invasive, drug-free therapies, which provide an alternative to traditional medication-based treatments. TMS, a therapy that uses magnetic pulses to stimulate areas of the brain involved in mood regulation, has been recognised for its effectiveness in treating a variety of conditions. Similarly, tDCS offers a non-invasive method of neuromodulation, allowing patients to receive treatment from the comfort of their own homes.
The integration of pharmacogenetic testing into Neuralia TMS’s offerings strengthens its commitment to personalised medicine. The testing provides important insights into how patients may respond to certain medications, ensuring that treatments are tailored to each person’s genetic makeup. This approach can be particularly valuable for patients who have not responded well to standard treatments or have experienced adverse effects from medications.
“The combination of pharmacogenetic testing with existing therapies brings a more comprehensive approach to treatment. Understanding how a patient’s genetics influence their response to medications allows for the development of a more effective care plan, reducing the need for trial-and-error,” said the spokesperson for Neuralia TMS. “This ultimately improves patient outcomes and supports better long-term management of their conditions.”
Neuralia TMS’s pharmacogenetic testing services are available to patients across Australia. The company remains at the forefront of offering non-invasive therapies, and the addition of pharmacogenetic testing further establishes Neuralia TMS as a leader in the field of personalised medicine. The testing process is straightforward, requiring only a small sample of saliva or blood to identify key genetic markers that influence drug metabolism.
Looking to the future, Neuralia TMS is focused on expanding its services and incorporating the latest advancements in medical technology. “As the field of pharmacogenetics continues to evolve, new opportunities will emerge to refine treatments and improve outcomes. Neuralia TMS is dedicated to staying at the cutting edge of these developments, ensuring patients continue to receive the most individualised and effective care available,” the spokesperson added.
Neuralia TMS remains committed to enhancing patient care through personalised, non-invasive treatments that address a wide range of mental health and chronic conditions. By integrating the latest scientific advancements, the company continues to ensure that patients receive tailored, evidence-based care designed to deliver optimal results.
For more information about Neuralia TMS and its pharmacogenetic testing Australia services, please contact Neuralia TMS at 08 6230 3996 or via email at info@neuralia.com.au.
Media Contact
Organization: Neuralia TMS
Contact
Person: Dr Shanek Wick
Website:
https://www.neuraliatms.com.au/
Email:
info@neuralia.com.au
Contact Number: 61862303996
Country:Australia
The post Neuralia TMS Specialises in Pharmacogenetic Testing Across Australia appeared first on
Brand News 24.
It is provided by a third-party content
provider. Brand News 24 makes no
warranties or representations in connection with it.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Infobeat Today journalist was involved in the writing and production of this article.